373 related articles for article (PubMed ID: 28748558)
21. MYC and aggressive B-cell lymphomas.
Slack GW; Gascoyne RD
Adv Anat Pathol; 2011 May; 18(3):219-28. PubMed ID: 21490439
[TBL] [Abstract][Full Text] [Related]
22. Application of 2016 WHO classification in the diagnosis of paediatric high-grade
Zhang L; Brown LE; Bowen LM; McCarthy LC; Cooley LD; Repnikova E; Gener MA; Garola R; August KJ; Hays JA; Zwick DL; Li W
J Clin Pathol; 2020 Sep; 73(9):563-570. PubMed ID: 31964683
[TBL] [Abstract][Full Text] [Related]
23. Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms-Updated Classification and New Concepts.
Kurz KS; Ott M; Kalmbach S; Steinlein S; Kalla C; Horn H; Ott G; Staiger AM
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190213
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina.
Bürgesser MV; Gualco G; Diller A; Natkunam Y; Bacchi CE
Ann Diagn Pathol; 2013 Jun; 17(3):250-5. PubMed ID: 23246412
[TBL] [Abstract][Full Text] [Related]
25. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification.
Jaffe ES; Pittaluga S
Hematology Am Soc Hematol Educ Program; 2011; 2011():506-14. PubMed ID: 22160082
[TBL] [Abstract][Full Text] [Related]
26. The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification.
Menon MP; Pittaluga S; Jaffe ES
Cancer J; 2012; 18(5):411-20. PubMed ID: 23006945
[TBL] [Abstract][Full Text] [Related]
27. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
Gebauer N; Bernard V; Feller AC; Merz H
Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112
[TBL] [Abstract][Full Text] [Related]
28. Burkitt lymphoma (BL): reclassification of 39 lymphomas diagnosed as BL or Burkitt-like lymphoma in the past based on immunohistochemistry and fluorescence in situ hybridization.
Kodet R; Mrhalová M; Stejskalová E; Kabícková E
Cesk Patol; 2011 Jul; 47(3):106-14. PubMed ID: 21887927
[TBL] [Abstract][Full Text] [Related]
29. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?
Thomas DA; O'Brien S; Faderl S; Manning JT; Romaguera J; Fayad L; Hagemeister F; Medeiros J; Cortes J; Kantarjian H
Curr Hematol Malig Rep; 2011 Mar; 6(1):58-66. PubMed ID: 21191675
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements.
Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Arakawa F; Niino D; Ohshima K
Pathol Int; 2015 Oct; 65(10):519-27. PubMed ID: 26224092
[TBL] [Abstract][Full Text] [Related]
31. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.
Sesques P; Johnson NA
Blood; 2017 Jan; 129(3):280-288. PubMed ID: 27821509
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas.
Behdad A; Bailey NG
Surg Pathol Clin; 2016 Mar; 9(1):41-54. PubMed ID: 26940267
[TBL] [Abstract][Full Text] [Related]
33. Double-hit B-cell lymphomas.
Aukema SM; Siebert R; Schuuring E; van Imhoff GW; Kluin-Nelemans HC; Boerma EJ; Kluin PM
Blood; 2011 Feb; 117(8):2319-31. PubMed ID: 21119107
[TBL] [Abstract][Full Text] [Related]
34. [Grey zone lymphomas: limitations of the classification of aggressive B-cell lymphomas].
Ott MM; Horn H; Rosenwald A; Ott G
Pathologe; 2013 May; 34(3):225-32. PubMed ID: 23494279
[TBL] [Abstract][Full Text] [Related]
35. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
Bellan C; Stefano L; Giulia de F; Rogena EA; Lorenzo L
Hematol Oncol; 2010 Jun; 28(2):53-6. PubMed ID: 19844983
[TBL] [Abstract][Full Text] [Related]
36. [Classification of aggressive B-cell lymphomas : News and open questions].
Rosenwald A; Menter T; Dirnhofer S
Pathologie (Heidelb); 2023 May; 44(3):166-172. PubMed ID: 36918411
[TBL] [Abstract][Full Text] [Related]
37. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology.
Carbone A; Gloghini A; Aiello A; Testi A; Cabras A
Hum Pathol; 2010 May; 41(5):621-31. PubMed ID: 20398809
[TBL] [Abstract][Full Text] [Related]
38. Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas.
Johnson PC; Abramson JS
Oncology (Williston Park); 2022 Aug; 36(8):499-505. PubMed ID: 36001789
[TBL] [Abstract][Full Text] [Related]
39. Diffuse large B-cell lymphomas and burkitt lymphoma.
de Leval L; Hasserjian RP
Hematol Oncol Clin North Am; 2009 Aug; 23(4):791-827. PubMed ID: 19577170
[TBL] [Abstract][Full Text] [Related]
40. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
